Featured Research

from universities, journals, and other organizations

Leading Cancer Institute Tests Novel Monitoring Technique

Date:
April 18, 2000
Source:
NASA/Jet Propulsion Laboratory
Summary:
A cancer detection technique that uses an advanced sensor developed at NASA's Jet Propulsion Laboratory, Pasadena, CA, is being tested by the prestigious Dana-Farber Cancer Institute, Boston, MA, for its use in monitoring the effectiveness of cancer treatment in patients.

A cancer detection technique that uses an advanced sensor developed at NASA's Jet Propulsion Laboratory, Pasadena, CA, is being tested by the prestigious Dana-Farber Cancer Institute, Boston, MA, for its use in monitoring the effectiveness of cancer treatment in patients.

The sensor is part of a device called the BioScan System™, developed by OmniCorder Technologies, Inc., Stony Brook, NY. OmniCorder has been developing and testing the system for three years and received Food and Drug Administration clearance to market it in December.

"Since we announced the BioScan System's clearance by the FDA, we have been inundated with requests to install and test the unit in clinics and hospitals across the country and overseas for a variety of cancer as well as other disease applications," said OmniCorder president and CEO Mark Fauci. "We selected the Dana- Farber site because we feel that this center could best help us to have the largest and most immediate impact on improving cancer treatment."

The application at Dana-Farber is different from those that have been tested at other sites. The BioScan System™ has been used to locate and confirm the presence of a cancerous breast lesion by detecting the cancer's ability to recruit new blood supply -- one of the hallmarks of a malignant lesion. The goal of the Dana-Farber research is to evaluate the BioScan System's ability to monitor biological effects of cancer treatment and to help physicians detect treatment-induced changes in cancerous lesions of the breast, skin and other organs. Armed with this information, they can better determine effectiveness of the treatments.

Dana-Farber is testing several new classes of anti-cancer products, including some -- called antiangiogenesis factors -- specifically designed to limit cancer growth by inhibiting its blood supply. (Angiogenesis is the formation and differention of blood vessels.) The BioScan System™ was designed to detect minute changes in blood supply to cancerous lesions and may help doctors measure precisely any decrease in blood supply to the cancer caused by these new treatments.

"Current technologies to monitor the effects of cancer treatment might miss important biologic and clinical effects, especially of newer treatment strategies such as antiangiogenesis approaches and drugs to induce differentiation," said Dr. George D. Demetri, medical director, Center for Sarcoma and Bone Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School in Boston. Drs. Demetri and Milos Janicek, from Dana-Farber's diagnostic oncoradiology division, will be co-principal investigators in the study.

"The technology harnessed by BioScan -- if it proves what we hope it will -- has the potential to provide this ability for researchers and clinicians who might otherwise miss subtle yet important effects of new drugs," Demetri said. "By doing so, it could have a substantial effect on developing new therapeutic approaches to cancer, such as directing researchers to optimize biologically active doses and even reducing the time it takes to demonstrate a drug's efficacy for FDA registration. It will be important to correlate the findings of this technology with clinical outcomes. With this type of tool, it is conceivable that once a drug has been approved, the same technology would allow us to monitor and individualize cancer treatment on a patient-by- patient basis."

OmniCorder is exclusively licensed by JPL to use the sensor technology, called Quantum Well Infrared Photodetector, and also holds licenses from other organizations. OmniCorder is a leading developer of non-invasive infrared disease detection systems. The JPL sensor has also been used in terrestrial applications, such as locating hot spots during fires, and it has potential uses for search and rescue, spotting faulty welds and blockages, and volcano observation. It also will fly sometime in the next several months on a small space technology research vehicle mission to detect the severity of radiation in the Van Allen Belt.

JPL is a division of the California Institute of Technology in Pasadena.


Story Source:

The above story is based on materials provided by NASA/Jet Propulsion Laboratory. Note: Materials may be edited for content and length.


Cite This Page:

NASA/Jet Propulsion Laboratory. "Leading Cancer Institute Tests Novel Monitoring Technique." ScienceDaily. ScienceDaily, 18 April 2000. <www.sciencedaily.com/releases/2000/04/000406090040.htm>.
NASA/Jet Propulsion Laboratory. (2000, April 18). Leading Cancer Institute Tests Novel Monitoring Technique. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2000/04/000406090040.htm
NASA/Jet Propulsion Laboratory. "Leading Cancer Institute Tests Novel Monitoring Technique." ScienceDaily. www.sciencedaily.com/releases/2000/04/000406090040.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins